Objective: To review nivolumab for the treatment of classical Hodgkin lymphoma (cHL). Data Sources: Literature searches were conducted in Medline (1946 to May week 3 2017), EMBASE (1974 to 2017 week 22), and Google Scholar using the terms Hodgkin lymphoma AND nivolumab. Study Selection and Data Extraction: Two clinical trials (phase I and phase II) were identified. Data Synthesis: Nivolumab inhibits programmed death receptor-1 allowing for increased T-cell mediated immune surveillance of tumors. Nivolumab was evaluated in cHL patients after failure of autologous stem cell transplantation and brentuximab vedotin consolidation. Patients received nivolumab 3 mg/kg every 2 weeks. In the phase I trial, the objective response rate was 87% (95% confidence interval [CI] = 66-97) and the rate of progression-free survival (PFS) at 24 weeks was 86% (95% CI = 62-95). The most common adverse events (AE) included rash (22%) and decreased platelet count (17%). Following extended follow-up at a median of 86 weeks, 50% of the initial responders maintained a durable response. In the phase II clinical trial, 53 patients (66.3%, 95% CI = 54.8-76.4) achieved an objective response and PFS at 6 months was 76.9% (95% CI = 64.9-85.3). The common AE were fatigue (25%), infusion-related reactions (20%), and rash (16%). After further follow-up at a median of 15.4 months, 12-month overall survival was 94.9% (median overall survival not reached). Conclusions: Nivolumab is an effective option in treating patients with relapsed/refractory cHL with an acceptable safety profile. Further studies are needed to investigate the role of nivolumab for the treatment of cHL.
American Cancer Society. Cancer Facts and Figures, 2017. Atlanta, GA: American Cancer Society; 2017.
2.
EichenauerDAEngertAAndreM. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3 suppl):iii70-iii75. doi:10.1093/annonc/mdu181.
3.
PeralesMACeberioIArmandP. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:971-983. doi:10.1016/j.bbmt.2015.02.022.
4.
MartinezCCanalsCSarinaB. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430-2434. doi:10.1093/annonc/mdt206.
5.
AraiSFanaleMdeVosS. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531-2533. doi:10.3109/10428194.2013.798868.
6.
ChenBJChapuyBOuyangJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462-3473. doi:10.1158/1078-0432.CCR-13-0855.
7.
GreenMRMontiSRodigSJ. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-3277. doi:10.1182/blood-2010-05-282780.
RomeroPCerottiniJSpeiserDE.The human T cell response to melanoma antigens. Adv Immunol. 2006;92:187-224. doi:10.1016/S0065-2776(06)92005-7.
11.
DrakeCGJaffeeEPardollDM.Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. doi:10.1016/S0065-2776(06)90002-9.
12.
TopalianSLDrakeCGPardollDM.Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-212. doi:10.1016/j.coi.2011.12.009.
13.
McDermottDFAtkinsMB.PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2:662-673. doi:10.1002/cam4.106.
14.
KeirMEButteMJFreemanGJSharpeAH.PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi:10.1146/annurev.immunol.26.021607.090331.
15.
FengYBajajGWangXAgrawalSGuptaMRoyA.Model-based analysis of nivolumab to support clinical pharmacology profiling in subjects with solid tumors (abstract). Clin Pharmcol Ther. 2015;97(1 suppl):S41. doi:10.1002/psp4.12143.
16.
Naumann-BartschNStachelDChadaM. Nivolumab as salvage therapy in pediatric patients with relapsed and refractory lymphomas (abstract). Blood. 2016;128:5414.
17.
ForanAENadelHRLeeAFSavageKJDeyellRJ. Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J Pediatr Hematol Oncol. 2017;39:e263-e266.
18.
YounesASantoroAShippM. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283-1294. doi:10.1016/S1470-2045(16)30167-X.
19.
AnsellSMLesokhinAMBorrelloI. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311-319. doi:10.1056/NEJMoa1411087.
20.
AnsellSArmandPTimmermanJMShippMABradley GarelikMBLesokhinAM.Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039) (abstract). Blood. 2015;126:583.
21.
TimmermanJEngertAYounesA. Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma (abstract). Paper presented at: 58th American Society of Hematology (ASH) Annual Meeting; December 4-6, 2016; San Diego, CA. Abstract 1110.
22.
LinchDCWinfieldDGoldstoneAH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-1054. doi:10.1016/0140-6736(93)92411-L.
23.
SchmitzNPfistnerBSextroM. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065-2071. doi:10.1016/S0140-6736(02)08938-9.
24.
MajhailNSWeisdorfDJDeforTE. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065-1072. doi:10.1016/j.bbmt.2006.06.006.
25.
SirohiBCunninghamDPowlesR. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19:1312-1319. doi:10.1093/annonc/mdn052.
26.
US Food and Drug Administration. Brentuximab vedotin approved for the post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm458815.htm. Accessed May 1, 2017.
27.
MoskowitzCHNademaneeAMassziT. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853-1862. doi:10.1016/S0140-6736(15)60165-9.
28.
CheahCYChiharaDHorowitzS. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27:1317-1323. doi:10.1093/annonc/mdw169.
29.
AlvarezISuredaACaballeroMD. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12:172-183. doi:S1083-8791(05)00673-7. doi:10.1016/j.bbmt.2005.09.009.
30.
KalacMLueJKLichtensteinE. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma [published online December16, 2016]. Br J Haematol. doi:10.1111/bjh.14449.
SuredaACanalsCArranzR. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the lymphoma working party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310-317. doi:10.3324/haematol.2011.045757.
33.
YounesAGopalAKSmithSE. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-2189. doi:10.1200/JCO.2011.38.0410.
Redbook Online [online database]. Greenwood Village, CO: Truven Health Analytics; 2017.
36.
ArmandPZinzaniPLCollinsG. Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma (abstract). Blood. 2016;128:3502.
37.
GodfreyJBishopMRSyedSHyjekEKlineJ.PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017;5:11. doi:10.1186/s40425-017-0211-z.
38.
OnizukaMKojimaMMatsuiK. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017;106(1):141-145.
39.
AngenendtLSchliemannCLutzM. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443-445. doi:10.1038/bmt.2015.266.
40.
CovutFPintoRCooperBW. Nivolumab before and after allogeneic hematopoietic cell transplantation (letter to the editor). Bone Marrow Transplant. 2017;52(7);1054-1056.
41.
El CheikhJMassoudRAbudalleI. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma (letter to the editor). Bone Marrow Transplant. 2017:28(10):2496-2502.
42.
HaverkosBMSchowinskyJKaplanJ. Checkpoint blockade for treatment of relapsed lymphoma following allogeneic hematopoietic cell transplant: use may be complicated by onset of severe acute graft versus host disease (abstract). Blood. 2016;128:1163.
43.
HerbauxCGauthierJBriceP. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin’s lymphoma. Blood. 2017;129:2471-2478. doi:10.1182/blood-2016-11-749556.
